Catania, September 25, 2015 – SIFI announces the expansion of its retinal disease management products with the launch of AVS Retina, Anti-VEGF Support.
AVS Retina is a nutraceutical containing botanicals, carotenoids and minerals, whose formula is conceived to support anti-VEGF drugs in the treatment, among others, of wet AMD (neovascular Age-related Macular Degeneration), a disease characterized by chronic inflammation and high levels of VEGF (Vascular Endothelial Growth Factor), which cause the development of edema. Anti-VEGF drugs induce a reduction of VEGF levels without a direct effect on inflammation and edema.
Fabrizio Chines, SIFI Executive Chairman, declared: “AVS Retina has a special importance because it is the first product launched during a new development plan and it is, once again, a tangible proof of SIFI’s commitment to providing ophthalmologists and their patients with new solutions to manage ophthalmic diseases”.
SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, Romania and Mexico with a staff of more than 330 people worldwide. Since June 2015 SIFI is backed by 21 Investimenti, private equity firm founded by Alessandro Benetton, to support the company’s international expansion and portfolio development strategy. For more information, please visit www.sifigroup.com.
For further information:
SIFI SpA Press & Communication Office
c/o CITYnet - Rome